Aurion Biotech
Focus: Aurion Biotech is a public biotech company founded in 2015 and headquartered in Seattle, focused on ocular transplant therapies, specifically corneal endothelial cell treatments for corneal edema.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
6
Should You Work at Aurion Biotech?
AI assessmentBest fit for specialists seeking niche ophthalmology expertise in a stable public setting, but limited scale and hiring velocity suggest constrained career growth.
Why Work Here
- Focused pipeline in a niche but high-value ophthalmology segment with multiple Phase 2/3 programs advancing toward potential approval
- Public company status provides stability and liquidity relative to private biotech peers
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
HCEC-1
Corneal EdemaClinical Trials (1)
NCT05309135A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction
Phase 1Help build intelligence for Aurion Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.